cs.CVNov 13, 2026

AG-JEPA: Anatomically Guided Joint Embedding Predictive Architecture for Neurodegenerative Representation Learning

Authors: Azad Singh, Ayantika Das, Amog Rao, Aiman Farooq, Anirban Porya, Ananya Shukla, Sowbhagya Suresh, Srinivasan Iyengar, 

Organizations: Microsoft Research India

Abstract

Brain MRI can reveal early signs of Alzheimers disease (AD) before measurable cognitive decline becomes apparent. However, during the transition from cognitively normal (CN) to mild cognitive impairment (MCI), the disease-related signals are often subtle and confined to only a few brain regions. Existing Joint Embedding Predictive Architecture (JEPA) models learn general structural representations but do not explicitly capture the anatomical regions affected in AD. We propose Anatomically Guided JEPA (AG-JEPA), which introduces anatomical tokens that interact with patch tokens during pretraining to learn region-specific representations from brain regions relevant to neurodegeneration. Building on this representation space, we further propose Prog-AG-JEPA, which models disease progression trajectory as a conditioned latent displacement within this space. We evaluate AG-JEPA across five downstream tasks spanning Alzheimer's disease diagnosis and progression prediction. AG-JEPA improves diagnosis and MCI prognosis, achieving an 8.4 percentage point AUROC gain over the strongest baseline on CN/MCI classification and a 7.1 percentage point gain on out-of-distribution CN/AD classification on the MR-RATE dataset, highlighting its effectiveness across both early-stage detection and cross-cohort generalization. For disease progression modeling, Prog-AG-JEPA consistently outperforms all baselines on future diagnosis and brain volume change prediction, demonstrating the value of anatomically grounded neurodegeneration representations for diagnosis and prognosis.

Figures & tables

Appendix figures & tables18 assets

Supplementary material from the paper’s appendix.

Appendix

Explore similar work

Jan 21, 2026

Anatomically Guided Latent Diffusion for Brain MRI Progression Modeling

Accurately modeling longitudinal brain MRI progression is crucial for understanding neurodegenerative diseases and predicting individualized structural changes. Existing state-of-the-art approaches, such as Brain Latent Progression (BrLP), often use multi-stage training pipelines with auxiliary conditioning modules but suffer from architectural complexity, suboptimal use of conditional clinical covariates, and limited guarantees of anatomical consistency. We propose Anatomically Guided Latent Diffusion Model (AG-LDM), a segmentation-guided framework that enforces anatomically consistent progression while substantially simplifying the training pipeline. AG-LDM conditions latent diffusion by directly fusing baseline anatomy, noisy follow-up states, and clinical covariates at the input level, a strategy that avoids auxiliary control networks by learning a unified, end-to-end model that represents both anatomy and progression. A lightweight 3D tissue segmentation model (WarpSeg) provides explicit anatomical supervision during both autoencoder fine-tuning and diffusion model training, ensuring consistent brain tissue boundaries and morphometric fidelity. Experiments on 31,713 ADNI longitudinal pairs and zero-shot evaluation on OASIS-3 demonstrate that AG-LDM matches or surpasses more complex diffusion models, achieving highly competitive image quality and 15-20% reduction in volumetric errors in generated images. AG-LDM also exhibits markedly stronger utilization of temporal and clinical covariates (3.5-31.5x higher covariate sensitivity than BrLP) and generates biologically plausible counterfactual trajectories, accurately capturing hallmarks of Alzheimer's progression such as limbic atrophy and ventricular expansion. These results highlight AG-LDM as an efficient, anatomically grounded framework for reliable brain MRI progression modeling.
Jul 1, 2026

NeuroBridge: Bridging Multi-Task MRI Knowledge for Neurodegenerative Disease Diagnosis

INTRODUCTION: Accurate MRI-based identification of Alzheimer's disease (AD), mild cognitive impairment (MCI), and related dementias remains challenging because disease-related structural changes are often subtle and heterogeneous. We developed NeuroBridge, a clinically guided multi-task MRI framework for neurodegenerative disease diagnosis. METHODS: NeuroBridge integrates large-scale self-supervised MRI pretraining with hippocampal segmentation, hippocampal atrophy classification, and reconstruction objectives, followed by gated fusion fine-tuning. Performance was evaluated across ADNI and OASIS cohorts, including cross-cohort transfer, probability-based analysis, and opportunistic screening. RESULTS: NeuroBridge achieved the highest performance across evaluated classification tasks, reaching 88.17% accuracy for AD versus cognitively normal controls in ADNI and 82.78% in OASIS. The largest gains occurred in MCI-related and mixed-diagnosis settings. The framework demonstrated strong cross-cohort generalization, systematic associations between predicted-class probability and accuracy, and the feasibility of probability-based opportunistic screening. DISCUSSION: Clinically guided multi-task representation learning improves neurodegenerative MRI diagnosis beyond conventional single-task approaches. NeuroBridge provides a robust and scalable framework for dementia assessment and MRI-based opportunistic screening.
Aug 9, 2026

Parcel2Progression: An Anatomy-aware Longitudinal Framework for Alzheimer's Disease Diagnosis

Alzheimer's disease (AD) progression is a longitudinal process with subtle pathological cues in the early stages. Yet, computational constraints have limited most neuroimaging models to either compromise spatial information or limit the number of longitudinal scans. We aim to overcome this bottleneck and fully leverage high-resolution, variable-length T1w structural MRI (4D sMRI) scan sequences. We introduce Parcel2Progression (P2P), a Longitudinal Transformer Framework which tackles this challenge using an Atlas-guided Parcel Encoder that tokenizes 3D scans into a set of richer anatomically grounded representations. A Longitudinal Transformer then integrates irregular, arbitrary-length longitudinal visits with patient age. This synergy delivers two key advantages: (1) parcel-specific interpretability, and (2) computational tractability for long-term analysis, which scales linearly with the number of scans compared to a naive quadratic 4D ViT cost. P2P outperforms prior works and baselines in both MCI (Mild Cognitive Impairment) to AD conversion prediction and AD vs. CN (Cognitively Normal) classification tasks across ADNI, AIBL, and MIRIAD datasets. Leveraging longitudinal scans boosts performance over single-scan baselines by up to 5% and 7% in balanced accuracy for AD classification and MCI conversion prediction tasks, respectively. Interpretability analysis using parcel saliencies and attention rollouts reveals clinically consistent atrophy patterns in AD and MCI subjects. We also demonstrate the frameworks' reliability in anomaly detection using a synthetic dataset, and test the model's generalizability for other neurodegenerative diseases like Frontotemporal Dementia.